IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 21.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,405 shares of the company's stock after selling 8,878 shares during the period. Toronto Dominion Bank's holdings in IDEXX Laboratories were worth $13,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. Geode Capital Management LLC increased its stake in IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after purchasing an additional 37,734 shares during the last quarter. Bamco Inc. NY grew its position in shares of IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after buying an additional 82,264 shares during the last quarter. Invesco Ltd. raised its stake in IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after acquiring an additional 74,324 shares in the last quarter. Norges Bank acquired a new stake in IDEXX Laboratories during the 4th quarter worth $412,258,000. Finally, Northern Trust Corp lifted its position in IDEXX Laboratories by 18.6% in the fourth quarter. Northern Trust Corp now owns 912,874 shares of the company's stock valued at $377,419,000 after acquiring an additional 143,369 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total transaction of $537,372.04. Following the transaction, the director now owns 262 shares in the company, valued at approximately $134,599.88. The trade was a 79.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.98% of the stock is owned by insiders.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research analyst reports. Morgan Stanley lifted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday. Barclays raised their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Stifel Nicolaus raised their price objective on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded down $3.03 during trading hours on Friday, hitting $512.52. 1,221,827 shares of the company were exchanged, compared to its average volume of 652,599. The business has a 50-day moving average of $449.80 and a 200-day moving average of $437.32. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $530.60. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $41.22 billion, a price-to-earnings ratio of 48.03, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. IDEXX Laboratories's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.71 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.